期刊
INTERNATIONAL IMMUNOPHARMACOLOGY
卷 112, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.intimp.2022.109183
关键词
Molecular Mimicry; Hyperactive Immune System; SARS-COV-2; Autoimmune Disease
SARS-CoV-2 infection can lead to various clinical manifestations, either directly related to viral tissue damage or indirectly induced by the immune response. The virus's molecular mimicry can undermine the host's immune system and trigger autoimmunity. Autoimmune diseases like lupus and autoimmune thyroid disease have been linked to COVID-19, and monitoring for autoimmunity is important. Autoimmune drugs may be effective in treating COVID-19.
SARS-CoV-2 infection can produce a variety of clinical manifestations, which are either directly related to viral tissue damage or indirectly induced by the antiviral immune response. Molecular mimicry enables this virus to undermine self-tolerance in a host's immune system also immune system's attempts to eliminate SARS-COV-2 may trigger autoimmunity by hyper-activating the innate and adaptive immune systems. Auto immune dis-eases include Systemic lupus erythematosus, autoimmune thyroid diseases, Guillain-Barre syndrome, Immune thrombocytopenic purpura, and the detection of autoantibodies are the cues to the discovery of the potential of COVID-19 in inducing autoimmunity. As COVID-19 and autoimmune diseases share a common pathogenesis, autoimmune drugs may be an effective treatment option. Susceptible patients must be monitored for autoim-mune symptoms after contracting CVID-19. In light of the SARS-COV-2 virus' ability to induce autoimmunity in susceptible patients, will the various COVID-19 vaccines that are the only way to end the pandemic induce autoimmunity?
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据